

Indication	Acute Myeloid Leukaemia
Treatment Intent	Curative
Frequency and number of cycles	2 cycles only
Monitoring Parameters pre-treatment	<ul style="list-style-type: none"> • FBC, U&E LFT prior to each cycle. • ECG and Echo at baseline. • Proceed with first course of treatment regardless of FBC, deranged counts will be due to disease. • Proceed with second course when neutrophils $\geq 1.0 \times 10^9/L$ and platelets $\geq 100 \times 10^9/L$ but clinician discretion can be used. • Renal impairment: <ul style="list-style-type: none"> ○ Daunorubicin: SrCr 105 – 265 $\mu\text{mol/L}$ give 75% dose; SrCr > 265 $\mu\text{mol/L}$ give 50% dose. • Hepatic impairment: <ul style="list-style-type: none"> ○ Daunorubicin: bilirubin 20 – 50 $\mu\text{mol/L}$ give 75% dose; bilirubin > 50 $\mu\text{mol/L}$ give 50% dose ○ Cytarabine: bilirubin > 34 $\mu\text{mol/L}$ –give 50% dose- escalate on subsequent cycles in the absence of toxicity. • Maximum cumulative dose of Daunorubicin = 600mg/m² in patients with normal cardiac function, in patients with cardiac dysfunction or exposed to mediastinal irradiation maximum cumulative dose = 400mg/m². Check previous exposure to anthracyclines. • Central line required for Daunorubicin infusion, otherwise Daunorubicin could be given as bolus via peripheral line. • Dose Modification: *For patients >60 years of age dose reduction of daunorubicin cycle 1 should be considered, 50mg/m². • Common drug interactions (for comprehensive list refer to BNF/SPC): • 5-Fluorocytosine should not be administered with Cytarabine. • Caution is necessary with concurrent use of anthracyclines with cardiotoxic drugs, or drugs that reduce cardiac contractility. • Ciclosporin can cause increased concentration of daunorubicin.
References	SPC accessed online 21.10.21 BNF accessed on line 21.10.21 KMCC proforma HAEM-AML-003 and HAEM-AML-004

NB For funding information, refer to CDF and NICE Drugs Funding List

Protocol No	HAEM-AML-003	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V3	Written by	M.Archer
Supersedes version	V1	Checked by	H.Paddock (V3) P.Chan (V2) V3 updated inline with SPC
Date	15.09.2022	Authorising consultant (usually NOG Chair)	J.Osbourne/L.Banerjee (V3)

Cycle 1 DA3+10

Day	Drug	Dose	Route	Infusion Duration	Administration
Day 1	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m ²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
	DAUNORUBICIN	60mg/m ² *	IV	1 hour	NaCl 0.9% 100ml-250ml or bolus if no central line through the side arm of a fast running NaCl 0.9% iv infusion.
12 hrs later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m ²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 2	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m ²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
12 hrs later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m ²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 3	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m ²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
	DAUNORUBICIN	60mg/m ² *	IV	1 hour	NaCl 0.9% 100ml-250ml or bolus if no central line through the side arm of a fast running NaCl 0.9% iv infusion.
12 hrs later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m ²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 4	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m ²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
12 hrs later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m ²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 5	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m ²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
	DAUNORUBICIN	60mg/m ² *	IV	1 hour	NaCl 0.9% 100ml-250ml or bolus if no central line through the side arm of a fast running NaCl 0.9% iv infusion.
12 hrs later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m ²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion

Protocol No	HAEM-AML-003	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V3	Written by	M.Archer
Supersedes version	V1	Checked by	H.Paddock (V3) P.Chan (V2) V3 updated inline with SPC
Date	15.09.2022	Authorising consultant (usually NOG Chair)	J.Osbourne/L.Banerjee (V3)

Day	Drug	Dose	Route	Infusion Duration	Administration
Day 6	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
12 hrs later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 7	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
12 hours later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 8	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
12 hours later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 9	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
12 hours later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 10	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
12 hours later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
TTO	Drug	Dose	Route	Directions	
Day 1	Chlorhexidine mouthwash	10ml	TOP	QDS. Use as mouthwash, rinsing mouth for at least 1 minute	
	Allopurinol	300mg	PO	OD for 2 weeks	
	Aciclovir	400mg	PO	BD for 4 weeks	
Prescribe anti-fungal as per local formulary PPI as per local formulary					

Protocol No	HAEM-AML-003	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.			
Version	V3	Written by		M.Archer	
Supersedes version	V1	Checked by		H.Paddock (V3) P.Chan (V2) V3 updated inline with SPC	
Date	15.09.2022	Authorising consultant (usually NOG Chair)		J.Osbourne/L.Banerjee (V3)	

Cycle 2 DA3+8

Day	Drug	Dose	Route	Infusion Duration	Administration
Day 1	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
	DAUNORUBICIN	50mg/m²	IV	1 hour	NaCl 0.9% 100ml-250ml or bolus if no central line through the side arm of a fast running NaCl 0.9% iv infusion.
12 hrs later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 2	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
12 hrs later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 3	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
	DAUNORUBICIN	50mg/m²	IV	1 hour	NaCl 0.9% 100ml-250ml or bolus if no central line through the side arm of a fast running NaCl 0.9% iv infusion.
12 hrs later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 4	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
12 hrs later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 5	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
	DAUNORUBICIN	50mg/m²	IV	1 hour	NaCl 0.9% 100ml-250ml or bolus if no central line through the side arm of a fast running NaCl 0.9% iv infusion.
12 hrs later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion

Protocol No	HAEM-AML-003	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V3	Written by	M.Archer
Supersedes version	V1	Checked by	H.Paddock (V3) P.Chan (V2) V3 updated inline with SPC
Date	15.09.2022	Authorising consultant (usually NOG Chair)	J.Osbourne/L.Banerjee (V3)

Day	Drug	Dose	Route	Infusion Duration	Administration
Day 6	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 6 12 hrs later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 7	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
12 hours later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
Day 8	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
12 hours later	Ondansetron	8mg	PO	stat	
	CYTARABINE	100mg/m²	IV	bolus	through the side arm of a fast running NaCl 0.9% iv infusion
TTO	Drug	Dose	Route	Directions	
Day 1	Chlorhexidine mouthwash	10ml	TOP	QDS. Use as mouthwash, rinsing mouth for at least 1 minute	
	Allopurinol	300mg	PO	OD for 2 weeks Not required if in remission after cycle 1	
	Aciclovir	400mg	PO	BD for 4 weeks and consider for up to 3 months after completion of treatment.	
	Prescribe anti-fungal as per local formulary PPI as per local formulary				

Protocol No	HAEM-AML-003	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.		
Version	V3	Written by	M.Archer	
Supersedes version	V1	Checked by	H.Paddock (V3) P.Chan (V2) V3 updated inline with SPC	
Date	15.09.2022	Authorising consultant (usually NOG Chair)	J.Osbourne/L.Banerjee (V3)	